Navigation Links
Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
Date:9/3/2008

MUNICH, Germany, Sept. 3 /PRNewswire-FirstCall/ -- A sub-analysis of the TRITON-TIMI 38 clinical trial showed that treatment with prasugrel compared with clopidogrel significantly reduced the risk of new or recurrent heart attacks (7.4 percent vs. 9.7 percent, p<0.0001), regardless of whether the events occurred around the time of an artery-opening procedure known as percutaneous coronary intervention (PCI), or if they occurred spontaneously during the longer-term maintenance phase. The analysis was presented today at the European Society of Cardiology (ESC) in Munich, Germany.

The sub-analysis assessed the effect of prasugrel on new or recurrent heart attacks, occurring in the acute setting and during long-term medical treatment (up to 15 months) in 13,608 acute coronary syndromes (ACS) patients who were managed with PCI. New or recurrent heart attacks were classified according to the ESC Universal Definition of Myocardial Infarction as spontaneous (Type 1) or procedure-related (Type 4 or 5).(1) The analysis showed that prasugrel consistently and significantly reduced spontaneous (Type 1) heart attacks by 29 percent compared with clopidogrel (2.5 percent vs. 3.4 percent, p=0.0015) and procedure-related recurrent heart attacks (Type 4 or 5) 24 percent in prasugrel-treated patients compared with those taking clopidogrel (4.9 percent vs. 6.4 percent, p=0.0002).

Long-term treatment with prasugrel, continuing after 30 days for up to 15 months, significantly reduced the risk for patients who suffer any form of heart attack by 23 percent compared with clopidogrel (2.9 percent vs. 3.7 percent, p=0.01). In the sub-analysis, prasugrel was also shown to reduce the risk of a future severe heart attack (ST elevation myocardial infarction (STEMI), a more severe form of ACS with a higher risk of death) by more than 50 percent compared with clopidogrel (p=0.0001).

The main TRITON-TIMI 38 clinical trial, for which overall results were previously publishe
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
2. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
3. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
4. TRITON-TIMI 38 Stent Analysis Favors Prasugrel
5. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies
8. Hibernation-On-Demand Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss
9. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
10. New Study: Pine Bark Significantly Reduces Menstrual Pain
11. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008).... 26 Children whose eye...antly increased risk of developing mental illness ...yo Clinic study published this month in Pediatrics... Pediatrics. , , The retrospective study ex...rabismus (misaligned eyes) and compared them with ...
(Date:11/25/2008)...espondents against expanding statin use broadly in...LS, N.J., Nov. 25 JUPITER, a clini...rdiovascular risk of healthy patients with elevate...lder adults, according to a national poll directed...took part in the online poll conducted by medical ...
(Date:11/25/2008)...RNewswire-FirstCall/ -- CardioVascular,BioTherape...today that it has,dosed the first patient in Nort...ical trial to treat patients with severe coronary ...eatment of CORonary heart Disease) trial will incl...lled doses in approximately 120,patients with sev...
(Date:11/24/2008)... innovation leadership and long-term commitment to...ov. 24 Schering-Plough C...l update on boceprevir, its lead investigational o...ase III development. The company believes bocepre...est-in-class protease inhibitor for treating chron...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9UNC scientists turn human skin cells into insulin producing cells 4935 1UNC scientists turn human skin cells into insulin producing cells 4935 2Final Patient Enrolled In Large Data Registry of Incisionless Gastric Pouch and Stoma Reduction Procedure 26533 1Final Patient Enrolled In Large Data Registry of Incisionless Gastric Pouch and Stoma Reduction Procedure 26533 2Final Patient Enrolled In Large Data Registry of Incisionless Gastric Pouch and Stoma Reduction Procedure 26533 3Final Patient Enrolled In Large Data Registry of Incisionless Gastric Pouch and Stoma Reduction Procedure 26533 4The Childrens Hospital of Philadelphia Erects the Final Beam of its Newest Research Building 26529 1The Childrens Hospital of Philadelphia Erects the Final Beam of its Newest Research Building 26529 2The Childrens Hospital of Philadelphia Erects the Final Beam of its Newest Research Building 26529 3Multi Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3080 1Multi Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3080 2Multi Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3080 3Multi Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3080 4Multi Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3080 5
...--Apr 26, 2007 - Northfield,Laboratories Inc. (Nas...rch organization has informed the Company that the... III trauma trial with,PolyHeme(R), the Company,s ...bstitute, will not be complete until May., About N...nc. is a leader in developing an,oxygen-carrying r...
...emonstrates dramatic,benefits of adding Diovan to ...to superior outcomes for,Diovan patients , , , ... from the independent,Jikei Heart Study, published...d pressure lowering medication Diovan® to,conv... in,cardiovascular events and a 40% reduction in s...
Other Medicine Technology:Northfield Laboratories Investor Update 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7
(Date:12/1/2008)... ETHICON, Inc., a Johnson & J...ted the divestiture of its Professional Wound Care... of the transaction are not being disclosed. , ...ty Partners has acquired the Professional Wound Ca... wound care brands as PROMOGRAN Matrix Wound Dress...
(Date:12/1/2008)...h the agency,s goals, commitment and resources ,...sponding to criticism that it has done a poor job ...od and Drug Administration released a report Monda... Among the most important changes in 2008 was the ...with state and local health departments to protect...
(Date:12/1/2008)...The Arthritis Foundation announces the 2008 winner...rthritis. The recipients, Dr. Gerard Karsenty of t...r. Michel Nussenzweig of Rockefeller University re...ncements in the cure and control of rheumatic dise...arch in the development and function of the skelet...
(Date:12/1/2008)...wswire-USNewswire/ -- Americans United for Life ... legislative resolution opposing the federal "Free...atures to adopt the resolution immediately when th...rmaine Yoest, AUL President & CEO said, "The s... health. It protects and promotes the abortion in...
Breaking Medicine News(10 mins):Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 3Health News:FDA Touts Efforts to Enhance Food Safety 2Health News:FDA Touts Efforts to Enhance Food Safety 3Health News:FDA Touts Efforts to Enhance Food Safety 4Health News:Americans United for Life Urges State Legislatures to Oppose Federal Power Grab: Provides Model Resolution Denouncing Freedom of Choice Act (FOCA) 2
...ohn's disease do not have improved bone mineral de... vitamin D therapy. Crohn's is an inflammatory bow...the intestinal wall. It usually begins in the teen...iarrhea, and weight loss. Patients with Crohn's di...
...s more likely to kill high-risk women compared to ...chers based on findings of a recent study . 8,353 ...t high risk because of diabetes or multiple risk f...ssed for three years to determine how doctors mana...
...y researchers say combining a 6 percent salicylic ...ffective treatment option for plaque psoriasis, an...y, red and thickened skin . For the study 30 adult...ed for 12 weeks. Study participants randomly recei...
... risk factors may reduce the risk of dementia, say.../ which shows that cardiovascular risk factors in ...dementia in old age. Risk factors for cardiovascu...pertension, diabetes and smoking. Each of these ca...
Other Medicine News:
...nverted microscopy from Zeiss. It has outstanding ..., with innovative condensers and optimized fluores...cated documentation and adaptation options, outsta... And Axiovert 200 M, fully motorized, gives you th...
... hallmark of these stereozoom fluorescent microsco... The top (incident) circular 9W fluorescent ring l... shadows while remaining cool to the touch. Binocu...10x to 44x zoom magnification or high-power 20x to...
...esigned for scientific microscope imaging applicat...ras provides high-resolution, full-color images an...E 1394) high-speed interface. This "live" previewi...lance and auto exposure operations to further enha...
...nce photomicrography system that greatly simply ta...t difficult specimens. Designed with real life in ...complex problem of fluorescence photomicrography. ...he system utilizes special programs designed to ea...
Medicine Products: